Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 26.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 114,638 shares of the specialty pharmaceutical company's stock after buying an additional 23,896 shares during the period. Envestnet Asset Management Inc. owned about 0.19% of Jazz Pharmaceuticals worth $14,232,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in JAZZ. Focus Partners Wealth bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $551,000. CX Institutional bought a new position in shares of Jazz Pharmaceuticals in the first quarter worth approximately $4,316,000. Envestnet Portfolio Solutions Inc. increased its stake in shares of Jazz Pharmaceuticals by 38.9% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company's stock worth $542,000 after purchasing an additional 1,223 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Jazz Pharmaceuticals by 63.7% during the 1st quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock valued at $126,000 after purchasing an additional 395 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Jazz Pharmaceuticals in the first quarter valued at about $1,888,000. 89.14% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Piper Sandler restated an "overweight" rating and set a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Robert W. Baird lowered their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. Royal Bank Of Canada dropped their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Finally, Needham & Company LLC restated a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $181.71.

Jazz Pharmaceuticals Stock Down 1.7%

Shares of NASDAQ:JAZZ traded down $1.99 during trading on Friday, reaching $112.87. The stock had a trading volume of 564,069 shares, compared to its average volume of 834,599. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $6.83 billion, a P/E ratio of 15.05, a PEG ratio of 5.64 and a beta of 0.32. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06. The firm's 50-day simple moving average is $109.13 and its 200 day simple moving average is $118.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The company's revenue for the quarter was down .5% compared to the same quarter last year. During the same period last year, the firm earned $2.68 EPS. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Seamus Mulligan acquired 100,000 shares of the business's stock in a transaction on Friday, May 9th. The stock was bought at an average cost of $98.26 per share, for a total transaction of $9,826,000.00. Following the purchase, the director owned 100,000 shares in the company, valued at approximately $9,826,000. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the sale, the chief executive officer owned 439,307 shares in the company, valued at $51,113,369.45. This represents a 0.23% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,500 shares of company stock valued at $277,930. Insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.